The estimated Net Worth of Frank Pasqualone is at least $4.19 Milhão dollars as of 21 August 2017. Mr. Pasqualone owns over 4,000 units of Theravance Biopharma Inc stock worth over $1,726,758 and over the last 10 years he sold TBPH stock worth over $0. In addition, he makes $2,461,250 as Senior Vice President and Chief Commercial Operations Officer at Theravance Biopharma Inc.
Frank has made over 1 trades of the Theravance Biopharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of TBPH stock worth $105,360 on 21 August 2017.
The largest trade he's ever made was buying 4,000 units of Theravance Biopharma Inc stock on 21 August 2017 worth over $105,360. On average, Frank trades about 129 units every 0 days since 2014. As of 21 August 2017 he still owns at least 213,180 units of Theravance Biopharma Inc stock.
You can see the complete history of Mr. Pasqualone stock trades at the bottom of the page.
Frank Pasqualone serves as Senior Vice President and Chief Commercial Operations Officer of the Company. He joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with our spin-off from Innoviva. Prior to the spin-off, Mr. Pasqualone held the position of Senior Vice President, Operations at Innoviva since January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led the marketing group in the Diabetes business. Since leaving Bristol-Myers Squibb and prior to joining Theravance, Mr. Pasqualone was self-employed as a part-time consultant. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio.
As the Senior Vice President and Chief Commercial Operations Officer of Theravance Biopharma Inc, the total compensation of Frank Pasqualone at Theravance Biopharma Inc is $2,461,250. There are 4 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.
Frank Pasqualone is 64, he's been the Senior Vice President and Chief Commercial Operations Officer of Theravance Biopharma Inc since 2016. There are 7 older and 19 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
Frank's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BLVD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, eEli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: